DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR MALARONE PEDIATRIC

« Back to Dashboard

All Clinical Trials for Malarone Pediatric

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00298610 ↗	Safety and Efficacy Study of IV Artesunate to Treat Malaria	Completed	Military Infectious Diseases Research Program (MIDRP)	Phase 2	2006-03-01	The purpose of this study is to determine how GMP IV Artesunate is metabolized and cleared by individuals with uncomplicated malaria infection and to determine how fast it eliminates malaria infection from the body.
NCT00298610 ↗	Safety and Efficacy Study of IV Artesunate to Treat Malaria	Completed	U.S. Army Medical Research and Development Command	Phase 2	2006-03-01	The purpose of this study is to determine how GMP IV Artesunate is metabolized and cleared by individuals with uncomplicated malaria infection and to determine how fast it eliminates malaria infection from the body.
NCT00298610 ↗	Safety and Efficacy Study of IV Artesunate to Treat Malaria	Completed	U.S. Army Office of the Surgeon General	Phase 2	2006-03-01	The purpose of this study is to determine how GMP IV Artesunate is metabolized and cleared by individuals with uncomplicated malaria infection and to determine how fast it eliminates malaria infection from the body.
NCT00421473 ↗	Drug Interaction Study Between Atovaquone and Antiretroviral Agents in HIV-1 Infected Patients	Completed	Radboud University	Phase 4	2007-03-01	Malarone® (atovaquone/proguanil) is frequently used in malaria prophylaxis. Unfortunately, there are indications that certain anti-HIV agents may decrease atovaquone plasma levels by induction of atovaquone metabolism. For travelling HIV patients, the clinical consequences of these possible drug drug interactions are serious, since a diminished exposure to the anti-malarial drug will result in suboptimal prophylaxis of malaria and potential development of drug resistant strains of Plasmodium falciparum. The purpose of this study is to find out if HIV patients using HAART regimes with either lopinavir/ritonavir, atazanavir/ritonavir or efavirenz have lower atovaquone plasma levels than healthy volunteers after a single dose of atovaquone/proguanil.
NCT00444106 ↗	Evaluation of Potential Effect of Artemether - Lumefantrine and Malaria Drugs on Auditory Function	Completed	Novartis	Phase 4	2007-05-01	To evaluate the potential effects of artemether- lumefantrine on the auditory function
NCT00984256 ↗	Weekly Dosing of Malarone ® for Prevention of Malaria	Completed	U.S. Army Medical Research and Development Command	Phase 2	2009-09-01	The purpose of this study is to determine whether Malarone ®, which is a drug approved to prevent malaria when taken daily, will still effectively prevent malaria if taken weekly.

Clinical Trial Conditions for Malarone Pediatric

Condition Name

Condition Name for Malarone Pediatric
Intervention	Trials
Malaria	13
Malaria,Falciparum	2
Exercise	1
PCP	1

Condition MeSH

Condition MeSH for Malarone Pediatric
Intervention	Trials
Malaria	16
Malaria, Falciparum	3
Infections	2
Infection	2

Clinical Trial Locations for Malarone Pediatric

Trials by Country

Trials by Country for Malarone Pediatric
Location	Trials
Netherlands	8
United States	7
Kenya	1
Belgium	1
Colombia	1

Trials by US State

Trials by US State for Malarone Pediatric
Location	Trials
Maryland	5
New York	1
Washington	1

Clinical Trial Progress for Malarone Pediatric

Clinical Trial Phase

Clinical Trial Phase for Malarone Pediatric
Clinical Trial Phase	Trials
Phase 4	5
Phase 2	3
Phase 1/Phase 2	1

Clinical Trial Status

Clinical Trial Status for Malarone Pediatric
Clinical Trial Phase	Trials
Completed	18
Withdrawn	2
Not yet recruiting	1

Clinical Trial Sponsors for Malarone Pediatric

Sponsor Name

Sponsor Name for Malarone Pediatric
Sponsor	Trials
Radboud University	6
U.S. Army Medical Research and Development Command	3
Medicines for Malaria Venture	3

Sponsor Type

Sponsor Type for Malarone Pediatric
Sponsor	Trials
Other	31
U.S. Fed	8
Industry	5